Memorial Sloan Kettering Cancer Center
The purpose of this study is to test the safety of FMT in patients with C. difficile and cancer. In previous other studies, FMT has been shown to cure C. difficile when antibiotics have failed, but most of these studies have not included patients with cancer. The investigators want to prove that FMT is safe in this group of people so that doctors will feel more comfortable prescribing it for their patients with cancer.
C. Difficile Infection
Cancer
Fecal Microbiota Transplantation (FMT)
NA
Study Type : | INTERVENTIONAL |
Estimated Enrollment : | 10 participants |
Masking : | NONE |
Primary Purpose : | TREATMENT |
Official Title : | Safety of Fecal Microbiota Transplantation (FMT) for Recurrent or Refractory C. Difficile Infection in Patients With Solid Tumors |
Actual Study Start Date : | 2016-05-10 |
Estimated Primary Completion Date : | 2024-02-16 |
Estimated Study Completion Date : | 2024-02-16 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065